



Revision date 17-Jun-2025 Version 4 Page 1/13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP (Hospira Inc.)

Product Code(s) PZ03096

Trade Name: Magnesium Sulfate in 5% Dextrose Injection, USP

Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as anticonvulsant

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company Pfizer Ireland Pharmaceuticals

275 North Field Drive OSG Building

Lake Forest, Illinois 60045 Ringaskiddy, Co. Cork.

1-800-879-3477 Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

Signal word Not classified

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Hazard statements Not classified in accordance with international standards for workplace safety.

Supplemental Hazard Compound, not fully tested, additional hazards may exist.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

PBT & vPvB The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2/13

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

\sim	_	·A	\sim	
laz	a.	u	υu	15

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sodium hydroxide	**	-	215-185-5	Skin Corr.1A	Eye Irrit. 2 ::	No data	No data
(CAS #: 1310-73-2)			(011-002-00-6)	(H314)	0.5%<=C<2%	available	available
					Skin Corr. 1A ::		
					C>=5%		
					Skin Corr. 1B ::		
					2%<=C<5%		
					Skin Irrit. 2 ::		
	**		004 000 5	01: 0 44	0.5%<=C<2%	N	N. 1.4
+ SULPHURIC ACID	• •		231-639-5	Skin Corr. 1A	Eye Irrit. 2 ::	No data	No data
%			(016-020-00-8)	(H314)	5%<=C<15% Skin Corr. 1A ::	available	available
(CAS #: 7664-93-9)					C>=15%		
					Skin Irrit. 2 ::		
					5%<=C<15%		
NonHazardous					0704-041070		
Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
	-	registration	Index No)	according to	concentration		(long-term)
		number		Regulation	limit (SCL)		
				(EC) No.			
				1272/2008			
		1		[CLP]	1		

Page 3/13

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Water (CAS #: 7732-18-5)	93	-	231-791-2	Not classified	Not classified	No data available	No data available
Dextrose, monohydrate (CAS #: 5996-10-1)	5		Not Listed	Not classified	Not classified	No data available	No data available
Magnesium sulfate heptahydrate (CAS #: 10034-99-8)	1-2		Not Listed	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg		Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available		No data available	No data available
Magnesium sulfate heptahydrate 10034-99-8	>5000	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ SULPHURIC ACID % 7664-93-9	2140	No data available	0.375	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

+ Substance with a Union workplace exposure limit

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Move victim to fresh air.

Eye contact If symptoms persist, call a physician.

Skin contact Wash skin with soap and water. If skin irritation persists, call a physician.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

^{**} to adjust pH

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

Hazardous combustion products Formation of toxic gases is possible during heating or fire. Emits oxides of sulfur under

combustion.

Explosion data

Sensitivity to mechanical impact No information available. **Sensitivity to static discharge** No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Page 4/13

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing.

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

> When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors,

Page 5 / 13

HEPA filtration systems or other equivalent controls.

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Store as directed by product packaging. **Storage Conditions**

7.3. Specific end use(s)

General hygiene considerations

Specific use(s) Pharmaceutical product used as. anticonvulsant.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

ACGIH OEL (Ceiling) 2 mg/m³ **ACGIH TLV** Ceiling: 2 mg/m3

TWA-TMW: 2 mg/m³; inhalable fraction Austria

STEL-KZGW: 4 mg/m³ (8 X 5 min); inhalable fraction

TWA: 2.0 mg/m³; alkaline aerosols Bulgaria

Czech Republic 1 mg/m³

Ceiling: 2 mg/m³ Ceiling: 2 mg/m3; Denmark Estonia TWA: 1 mg/m³; STEL: 2 mg/m3;

Ceiling: 2 mg/m³; Finland

2 mg/m³ France

TWA-AK: 1 mg/m3; Hungary STEL-CK: 2 mg/m3;

Ireland STEL: 2 mg/m3; 2 mg/m³ Ceiling Limit Value

TWA: 0.5 mg/m³; Latvia TWA-NDS: 0.5 mg/m³; Poland STEL-NDSCh: 1 mg/m3;

Romania TWA: 1 mg/m³; STEL: 3 mg/m3;

TWA: 2 mg/m³; Slovakia

Spain STEL (VLA-EC): 2 mg/m3;

Switzerland TWA-MAK: 2 mg/m3; inhalable dust STEL-KZGW: 2 mg/m3; inhalable dust

OSHA PEL TWA: 2 mg/m³

(vacated) Ceiling: 2 mg/m3

United Kingdom STEL: 2 mg/m³;

+ SULPHURIC ACID ... %

ACGIH TLV TWA: 0.2 mg/m³ thoracic particulate matter Austria TWA-TMW: 0.1 mg/m³; inhalable fraction STEL-KZGW: 0.2 mg/m3 (); inhalable fraction

TWA: 0.05 mg/m3; respirable aerosol Bulgaria

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Czech Republic 1 mg/m³

0.05 mg/m³ Ceiling: 2 mg/m³ Page 6/13

Denmark TWA: 0.05 mg/m³; mist STEL: 0.1 mg/m³; mist

Estonia TWA: 0.05 mg/m³; particles that reach the upper respiratory tract

European Union

TWA: 0.05 mg/m³; mist (thoracic fraction)

TWA: 0.05 mg/m³; thoracic fraction

TWA: 0.05 mg/m³; thoracic fraction

STEL: 0.1 mg/m³; thoracic fraction

France 0.05 mg/m³

Germany DFG TWA-MAK: 0.1 mg/m³; I(1);inhalable fraction

Peak: 0.1 mg/m³; inhalable fraction

Germany TRGS

TWA-AGW; 0.1 mg/m³ (exposure factor 1); inhalable fraction

Hungary TWA-AK: 0.05 mg/m³; Ireland TWA: 0.05 ppm;

STEL: 0.15 ppm (calculated); Italy MDLPS TWA: 0.05 mg/m³; thoracic fraction, mist

ay MDEL 1

Ceiling Limit Value 1 mg/m³

Latvia TWA: 0.05 mg/m³; fog, which is defined as the thoracic fraction

NetherlandsTWA: 0.05 mg/m³; mist, thoracic fractionPolandTWA-NDS: 0.05 mg/m³; thoracic fractionRomaniaTWA: 0.05 mg/m³; thoracic fraction

Russia MAC: 1 mg/m³

Skin

Slovakia TWA: 0.05 mg/m³;

Spain TWA-(VLA-ED): 0.05 mg/m³; mist TWA-MAK: 0.1 mg/m³; inhalable dust STEL-KZGW: 0.2 mg/m³; inhalable dust

OSHA PEL TWA: 1 mg/m³

United Kingdom (vacated) TWA: 1 mg/m³ TWA: 0.05 mg/m³; mist STEL: 0.15 mg/m³; mist

8.2. Exposure controls

Personal protective equipment

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes.

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the

workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the

selection and use of personal protective equipment (PPE).

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Skin and body protection Impervious disposable protective clothing is recommended if skin contact with drug product

is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).

(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

Page 7/13

or international equivalent.).

Thermal hazards No information available.

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Liquid Color Colourless

Odor No information available.
Odor threshold No information available

<u>Property</u> <u>Values</u>

Melting point / freezing pointNo data availableBoiling point or initial boiling point and boiling rangeNo data availableFlammability (solid, gas)No data available

Lower and upper explosion limit/flammability limit

Lower explosion limit
Upper explosion limit
No data available
No data available
No data available
Autoignition temperature
No data available

Decomposition temperature

SADT (°C) No data available

pH 3.5-6.5

pH (as aqueous solution)

No data available

Kinematic viscosity

No data available

Dynamic viscosity

No data available

Solubility

No data available

Vapor pressure

No data available

Density and/or relative density

Bulk density

No data available

No data available

Bulk density
Liquid Density
No data available
Vapor density
No data available
No data available

Particle characteristics

Particle SizeNo information availableParticle Size DistributionNo information available

9.2. Other information

Molecular formula Mixture
Molecular weight Mixture

9.2.1. Information with regard to physical hazard classes

Oxidizing properties None

Page 8/13

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid None known.

10.5. Incompatible materials

Incompatible materials None known.

10.6. Hazardous decomposition products

Hazardous decomposition products Thermal decomposition products include. oxides of sulfur.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the active

ingredient(s).

Known Clinical Effects: Adverse effects associated with therapeutic use include flushing, sweating, decrease in

blood pressure (hypotension), circulatory failure, central nervous system, depression.

Acute toxicity Based on available data, the classification criteria are not met. Serious eye damage/eye irritation Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Skin corrosion/irritation Based on available data, the classification criteria are not met. Respiratory or skin sensitization Based on available data, the classification criteria are not met. STOT - single exposure Based on available data, the classification criteria are not met. STOT - repeated exposure Reproductive toxicity Based on available data, the classification criteria are not met. Germ cell mutagenicity Based on available data, the classification criteria are not met.

CarcinogenicityBased on available data, the classification criteria are not met. **Aspiration hazard**Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium sulfate heptahydrate

Rat Oral LDmin. 5000 mg/kg Mouse Oral LDmin. 3000 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ SULPHURIC ACID %	= 2140 mg/kg (Rat)	-	= 0.375 mg/L (Rat) 4 h

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Magnesium sulfate heptahydrate

Fertility and Embryonic Development Rat Oral 450 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Magnesium sulfate heptahydrate

Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity See below The International Agency for Research on Cancer (IARC) and the United States

National Toxicology Program (NTP) have classified 'occupational exposure to strong inorganic acid mists containing sulfuric acid' as a known human carcinogen. This classification applies only to sulfuric acid when generated as a mist. This classification is debated within the scientific community and there is disagreement as to whether or not a cause and effect relationship between cancer and 'occupational exposure to strong

Page 9/13

inorganic acid mists containing sulfuric acid' exists.

+ SULPHURIC ACID ... %

IARC Group 1 NTP Known

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should

be avoided. Based on available data, the classification criteria are not met.

<u>12.1. Toxicity</u>

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Page 10 / 13

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply
+ SULPHURIC ACID %	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Not applicable
Not applicable
Packing group:
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

PZ03096

Page 11/13

Revision date 17-Jun-2025 Version 4

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Wa	ater
----	------

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-791-2 AICS Present

Dextrose, monohydrate

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed

Magnesium sulfate heptahydrate

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed EINECS Not Listed AICS Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus % Not Listed 1000 lb **Hazardous Substances RQs** California Proposition 65 Not Listed Present **TSCA EINECS** 215-185-5 **AICS** Present Standard for Uniform Scheduling of Medicines and Schedule 5 Poisons (SUSMP) Schedule 6

+ SULPHURIC ACID ... %

CERCLA/SARA Section 313 de minimus % 1.0 % Hazardous Substances RQs 1000 lb California Proposition 65 Carcinogen TSCA Present EINECS 231-639-5 AICS Present Standard for Uniform Scheduling of Medicines and Schedule 6

Poisons (SUSMP)

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905 Not applicable

Chemical name	Netherlands - List of Carcinogens	Netherlands - List of Mutagens	Netherlands - List of Reproductive Toxins
+ SULPHURIC ACID % 7664-93-9	Present	-	-

Page 12 / 13

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018

Storage of Hazardous Material

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20

Major Accidents Ordinance SR 814.012

Not applicable
Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH	Substance subject to authorization per
	Annex XVII	REACH Annex XIV
Sodium hydroxide	75	-
1310-73-2		
+ SULPHURIC ACID %	75	-
7664-93-9		

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Chemical name	Limit value	Upper limit value for the purpose of licensing under article 5(3)	Reportable explosives precursors
+ SULPHURIC ACID % 7664-93-9	15 %w/w	40 %w/w	-

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Product Name Magnesium Sulfate in 5% Dextrose Injection, USP

(Hospira Inc.)

Revision date 17-Jun-2025 Version 4

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage

Data Sources: Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Page 13 / 13

Revision date 17-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.